Citigroup Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 73.4%

Neg 73.4% Neu 0% Pos 0%

Citigroup analyst Laura Sutcliffe maintains Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and lowers the price target from $22.5 to $22.